Phase 3 Readout~month

Phase 3 Topline: IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Indication
Acute Myeloid Leukemia; Relapse/Recurrence

Other upcoming events for GPCR

Phase 2 ReadoutPhase 2 Readout: aleniglipron
Patent ExpiryPatent/Exclusivity Expiry: LEGUBETI
Patent ExpiryPatent/Exclusivity Expiry: ACETAMINOPHEN
Patent ExpiryPatent/Exclusivity Expiry: APADAZ
Patent ExpiryPatent/Exclusivity Expiry: OFIRMEV

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. — GPCR Phase 3 Readout | BioSniper